Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...
Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...
Insider Monkey on MSN6d
Is Teva Pharmaceutical (TEVA) Trading at a Discount?Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...
Pharmaceutical Technology on MSN1d
Teva and Alvotech launch ustekinumab biosimilar injection in USTeva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
GlobalData on MSN1d
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...
Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...
In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback